Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03024684

Acronym

SHOT

Enrollment

240

Registered

2017-01-19

Start date

2017-01-03

Completion date

2027-01-31

Last updated

2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HepatoCellular Carcinoma

Keywords

Hepatocellular carcinoma, statin, curative ablation

Brief summary

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment

Detailed description

This is a multi-center double-blind randomized placebo-controlled trial. A total of 240 patients with HCC at BCLC stage 0 or A will be enrolled from 8 hospitals in Taiwan. After complete ablation or hepatic resection of the tumor(s), participants are randomized 1:1 to receive either atorvastatin 10mg once daily (intervention group) or matched placebo (control group) for 3 years. During the 3-year period, patients are monitored for recurrence of HCC by dynamic computed tomography (or magnetic resonance image) every 4 months. They will be followed up until death, withdrawal from participation, study termination, or 3 years after the ablative treatment. The primary endpoint is to compare the 3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart. Secondary endpoints are occurrence of clinical complications related to hepatic decompensation (including gastroesophageal variceal bleeding, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome), liver-related mortality, and all-cause mortality.

Interventions

DRUGAtorvastatin

Atorvastatin 10mg daily

DRUGPlacebo Oral Tablet

Placebo one tablet daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation or hepatic resection could be eligible. * Individuals who had single HCC (size \> 5.0 cm) received hepatic resection would be eligible * Individuals with prior history of HCC who had ever received curative ablation or hepatic resection without any recurrence for more than 2 years could be eligible if they had a new episode of recurrent HCC which could meet either of the former two criteria. * After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of local residual or recurrent tumors according to the dynamic CT or MRI could be enrolled * The diagnosis of fresh HCC should be compatible with either pathological report or meet the criteria of AASLD guidelines

Exclusion criteria

* Undetermined nature of hepatic tumor * HCC with extrahepatic metastasis or major vascular invasion * With other malignant disease * Child Pugh score \>7 * Previous history of CAD event (angina, unstable angina, acute myocardial infarction) or ischemic stroke * Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline) * Advanced CKD (eGFR\<30) or ESRD * Severe comorbidity with life expectancy \< 2 years * Allergy to statin

Design outcomes

Primary

Measure	Time frame	Description
3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart	3 years	Recurrence rate of HCC

Secondary

Measure	Time frame	Description
occurrence of clinical complications related to hepatic decompensation	3 years	clinical complications or hepatic decompensation

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026